Re-Irradiation of recurrent non-small cell lung icancer
dc.contributor.author | Hunter, B. | |
dc.contributor.author | Crockett, Cathryn | |
dc.contributor.author | Faivre-Finn, Corinne | |
dc.contributor.author | Hiley, C. | |
dc.contributor.author | Salem, Ahmed | |
dc.date.accessioned | 2021-04-06T15:07:00Z | |
dc.date.available | 2021-04-06T15:07:00Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Hunter B, Crockett C, Faivre-Finn C, Hiley C, Salem A. Re-Irradiation of Recurrent Non-Small Cell Lung Cancer. Semin Radiat Oncol. 2021;31(2):124-32. | en |
dc.identifier.pmid | 33610269 | en |
dc.identifier.doi | 10.1016/j.semradonc.2020.11.009 | en |
dc.identifier.uri | http://hdl.handle.net/10541/623837 | |
dc.description.abstract | Locoregional recurrence occurs in 10%-30% of non-small cell lung cancer (NSCLC) after treatment with definitive (chemo)radiotherapy. Re-irradiation is the main curative-intent treatment option for these patients; however, it represents a therapeutic challenge for thoracic radiation oncologists. Re-irradiation practices are variable worldwide with lack of agreement on the optimal dose or the cumulative maximum dose acceptable for critical organs. The role of re-irradiation in NSCLC is also not clearly defined in the era of immunotherapy. In this review, we will present published and on-going re-irradiation studies for recurrent NSCLC. We will appraise available evidence for critical organ dose constraints and provide a framework for future therapeutic approaches and trials | en |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/j.semradonc.2020.11.009 | en |
dc.title | Re-Irradiation of recurrent non-small cell lung icancer | en |
dc.type | Article | en |
dc.contributor.department | The Royal Marsden Hospital, Chelsea, UK | en |
dc.identifier.journal | Seminars in Radiation Oncology | en |
dc.description.note | en] |